Search

Your search keyword '"Hodge, Rachel A."' showing total 274 results

Search Constraints

Start Over You searched for: Author "Hodge, Rachel A." Remove constraint Author: "Hodge, Rachel A."
274 results on '"Hodge, Rachel A."'

Search Results

1. Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

3. Mechanisms of Germline Stem Cell Competition across Species.

4. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

5. Age-related decline of occluding junctions in Drosophila melanogaster

6. Supplementary Figure S5 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

7. Supplementary Table S2 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

8. Data from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

9. Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma

13. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

14. Prevalence of incidental germline variants detected via tumor-only mesothelioma genomic profiling

15. Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFRMutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in VitroDiagnostic

17. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

18. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

20. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer

22. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)

25. Human Sex-Specific Synaptic Adhesion Proteins NLGN4X and NLGN4Y Regulate the Dual Innervation of Dendritic Spines

28. Osimertinib in ResectedEGFR-Mutated Non–Small-Cell Lung Cancer

29. Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib.

32. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC

39. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

42. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.

46. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

47. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

48. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Catalog

Books, media, physical & digital resources